In its latest round of job cuts, Novartis is to axe nearly 2,000 of its US workforce, mostly from the sales division. The Swiss drugmaker is trimming costs as the patent runs out for its top-selling blood pressure drug Diovan, which means competitors can make it cheaper. ... http://www.euronews.net/
